Objectives-To determine the effects of early treatment with captopril on haemodynamic function, neuroendocrine biochemistry, left ventricular structure, clinical outcome, and exercise capacity over one year from acute myocardial infarction.
placebo controlled comparison of captopril and placebo.
Setting-Coronary care units and cardiology departments of two university teaching hospitals in Glasgow.
Patients-99 haemodynamicaly stable patients with acute myocardial infarction, selected on clinical grounds as being at risk of late ventricular dilatation.
Intervention-Captopril or identical placebo started between six and 24 hours after start of symptoms and continued for 12 months. Target maintenance dose was 25 mg three times a day.
Main outcome measures-(a) Acute haemodynamic effects of treatment; (b) neuroendocrine biochemistry from admission to two months; and (c) change in echocardiographic measures of left ventricular size, clinical outcome, and exercise capacity after 12 months of treatment with a separate analysis of the effects of one month of treatment withdrawal on left ventricular volumes.
Results-Captopril caused acute reductions in mean (SEM) pulmonary artery pressure (0.69) mm Hg) and systemic vascular resistance (260 (103)) dyn. s. cm-5). Over the first 10 hours captopril reduced mean arterial pressure by 12*1 (2.4) mm Hg compared with 3-8 (1. 9) mm Hg in the placebo group. No patient had to be withdrawn from the captopril group because of hypotension. From day 1 onwards systolic and diastolic arterial pressures in the captopril treated group were slightly but not significantly lower than on placebo. There was no difference in the incidence of ventricular or supraventricular arrhythmia with treatment. Captopril prevented the day 3 peak in angiotensin II that occurred in the placebo group (peak concentration (interquartile range): 10-1 (48-419.4) pg/ml v 16*8 (4.3-46. 3) pg/ml)) but had no effect on atrial natriuretic factor, arginine vasopressin, or catecholamines. Plasma atrial natriuretic factor remained above normal in both groups at two months after infarction. After one year left ventricular volume indices had increased less on captopril than on placebo: left ventricular end systolic volume index 5 4 mlum' v 14*7 ml/ml (95% confidence interval (95% CI) of difference -14-6 to -3 9; p=0O0011); left ventricular end diastolic volume index 8-4 ml/ml v 19*0 mllm' (95% CI of difference, -17-0 to -4-2; p=00016). Withdrawal of captopril for one month did not affect ventricular volumes. There was no difference in exercise capacity.
Conclusions-Captopril started between six and 24 hours after acute myocardial infarction is not associated with significant hypotension. It suppresses activation of the renin angiotensin system but has no effect on plasma concentrations of other neurohormones. Atrial natriuretic factor remains raised at two months after myocardial infarction. Captopril significantly decreases left ventricular dilatation. This effect is not lost after one month of treatment withdrawal and is thus due to an alteration of left ventricular structure and not to a short lived haemodynamic action of captopril. Long Before the first dose of trial medication an indwelling forearm cannula was inserted and after 30 minutes supine rest venous blood was drawn for assay of atrial natriuretic factor, renin, angiotensin II, arginine vasopressin, adrenaline, and noradrenaline. Sampling was repeated by the same technique at day 3, days seven to 10, and at two months. At all time points from admission sampling was performed about two hours after the last dose of trial medication. All assays were performed in the laboratories of the Medical Research Council Blood Pressure Unit with previously described techniques.""'7 Normal ranges are: atrial natriuretic factor 5-50 pg/ml; renin 9-50 pu/ml; angiotensin II <20 pg/ml, arginine vasopressin 0 3-0 7 pg/ml; adrenaline <1 nmolIl; noradrenaline <5 nmol/l.
ECHOCARDIOGRAPHY
Cross sectional echocardiography was performed on days 1, 3, and 7 to 10 and at one, two, six, 12 
Results

CLINICAL OUTCOMES
At baseline the two treatment groups were well matched except for an inequality in the distribution of patients with a previous myocardial infarction (table 1) . Over one year of follow up there were eight deaths (four sudden) in the captopril group and 10 (six sudden) in the placebo group. Thirteen of these patients died within two months of infarction. All five deaths between two months and one year were in the placebo group. Table 2 shows only twenty two patients were withdrawn from the study medication. Seventy three patients were available for analysis at the end of the study including 14 patients who had been withdrawn from the study medication but who had continued blinded follow up. There was no difference in the use of non-trial cardiac drugs at one year. Time from first dose of trial medication (h)
ARRHYTHMIAS
There was no difference in the incidence of ventricular or supraventricular arrhythmias between the treatment groups either after admission or before discharge.
NEUROENDOCRINE RESPONSES
Pretreatment concentrations of all hormones except adrenaline tended to be higher in the captopril group (table 5 ). In the placebo group concentrations of renin and angiotensin II rose from admission to day 3. This trend was present even in those patients not treated with diuretics. In this subgroup median plasma renin concentrations rose from 27 gu/ml on admission to 64 gu/ml at day 3, and fell to 39,u/ml at days 7-10. Corresponding angiotensin II concentrations were 110 pg/ml, 13 6 pg/ml, and 8&7 pg/ml.
Captopril caused a considerable increase in renin concentration and suppressed the rise in angiotensin II seen in the placebo group. Plasma atrial natriuretic factor peaked at three days in both treatment groups, and remained above normal throughout the study Time from admission (months) We have confirmed the occurrence of a peak in plasma atrial natriuretic factor two to four days after infarction.'03' Previous studies have found concentrations of plasma atrial natriuretic factor to be raised for up to 15 days,32 but a persistent increased concentra- suggest that captopril might modify the [he tendency to a greater degree of neu-release of atrial natriuretic factor such that ndocrine activation in the captopril group secretion is increased for a given degree of baseline is consistent with the trend to atrial distension and is less sensitive to a fall her cardiac filling pressures and a higher in atrial pressure. This hypothesis, however, ik creatine kinase in these patients. We is not supported by the results of other studre confirmed previous findings of stimula-ies. Swedberg et al found a 20% fall in conof the renin angiotensin system three centrations of atrial natriuretic factor after six rs after acute myocardial infarction even in weeks of enalapril treatment in patients with absence of diuretic treatment9. The mech-severe chronic heart failure.'5 In acute dose sm for this effect remains uncertain but it studies in salt replete normal volunteers captopril has either no effect, 36 Concentrations of arginine vasopressin in this study are similar to those described previously. 9 In patients with stable heart failure long-term captopril treatment leads to a reduction in arginine vasopressin'9 but there is no effect with short term treatment either in stable heart failure40 or in acute left ventricular failure where concentrations are noticeably increased.33 In acute and chronic heart failure the effects of converting enzyme inhibition on catecholamines have been variable with either no effectll40 or a decrease in noradrenaline.27 41 At the time of entry to the present study median concentrations of both adrenaline and noradrenaline were in the upper reaches of the normal range and it would have been surprising had any effect of captopril been seen. The initial fall, however, in arterial pressure in the captopril group in the absence of a compensatory tachycardia provides indirect evidence of a sympatholytic effect.
We have shown that oral captopril started within 24 hours of symptoms greatly reduces left ventricular remodelling over the first year after acute myocardial infarction. Left ventricular dilatation begins within hours of transmural myocardial necrosis and is particularly rapid over the first [10] [11] [12] [13] [14] reduce the extent of ventricular enlargement from baseline in the placebo group. We deliberately selected patients at risk of ventricular dilatation. About 40% of the total increase in left ventricular volumes in our placebo patients occurred in the first 10 days after infarction but chamber dilatation continued over the course of the study. Similar persistence of ventricular dilatation has been found in other studies.' 44 The optimal duration of captopril treatment remains to be defined but our results suggest that it should be continued for at least a year and possibly indefinitely. The lack of a change in ventricular volumes in the captopril group after the month of treatment withdrawal confirms that the reduction in ventricular dilatation is structural and not due simply to a rapidly reversible haemodynamic effect. It does not allow us to determine the mechanism underlying the effect of captopril.
None of the patients in our study received thrombolytic treatment. Thrombolysis and a patent infarct related artery reduce the extent of ventricular remodelling4445 but captopril is none the less effective in attenuating ventricular dilatation in patients treated with streptokinase46 and probably in those treated with tissue plasminogen activator.47 A significant proportion of patients with acute myocardial infarction have either contraindications to the use of thrombolytics, present too late for effective thrombolysis, or fail to reperfuse. These are the patients who probably have most to gain from treatment with captopril.
We were unable to show any benefit of captopril treatment on aerobic exercise capacity and there was no correlation between exercise capacity and resting left ventricular function. Captopril improves exercise capacity in patients with congestive cardiac failure48 but few of our patients fell into this category. In both treatment groups maximal oxygen uptake was in the low normal range. 
